Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
IMMX
Stock Latest News
Ratings
Promising Interim Results from NEXICART-2 Trial Support Buy Rating for NXC-201
11d ago
IMMX
Premium
The Fly
Immix Biopharma files $13.45M common stock ATM offering
12d ago
IMMX
Premium
Company Announcements
Immix Biopharma Enters At The Market Offering Agreement
12d ago
8K
IMMX
Premium
The Fly
Immix Biopharma announces NXC-201 trial met primary endpoint
12d ago
IMMX
Premium
The Fly
Immix Biopharma expands U.S. clinical sites for NEXICART-2 trial
23d ago
IMMX
Premium
Ratings
Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201
4M ago
IMMX
Premium
The Fly
Immix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL Amyloidosis
4M ago
IMMX
Premium
The Fly
Immix Biopharma accelerates enrollment in U.S. AL amyloidosis trial of NXC-201
5M ago
IMMX
Premium
The Fly
Immix Biopharma announces data from four patients in NEXICART-2 U.S. trial
6M ago
IMMX
Premium
The Fly
Immix Biopharma announces publication of NXC-201 clinical results
6M ago
IMMX
Premium
The Fly
Immix Biopharma reports 75% CRR for NXC-201 in r/r AL amyloidosis patients
6M ago
IMMX
Premium
The Fly
Immix Biopharma: Ex-US study of NXC-201 produced 92% ORR in r/r AL Amyloidosis
9M ago
IMMX
Premium
The Fly
Immix Biopharma announces three more sites for NEXICART-2 trial
10M ago
IMMX
Premium
The Fly
Immix Biopharma awarded $8M CLIN2 grant
11M ago
IMMX
Premium
The Fly
Immix Biopharma doses first patient in U.S. AL amyloidosis trial with NXC-201
11M ago
IMMX
Premium
The Fly
Immix Biopharma initiated with a Buy at H.C. Wainwright
12M ago
IMMX
Premium
Company Announcements
Immix Biopharma Shareholders Back Growth and Governance Changes
1y ago
8K
IMMX
Premium
The Fly
Immix Biopharma announces NXC-201 relapsed/refractory AL Amyloidosis data
1y ago
IMMX
Premium
The Fly
Immix Biopharma management to meet with B. Riley
1y ago
IMMX
Premium
The Fly
Immix Biopharma management to meet with B. Riley
1y ago
IMMX
Premium
The Fly
Immix Biopharma: EC grants orphan drug designation to NXC-201
1y ago
IMMX
Premium
The Fly
Immix Biopharma says ‘on track’ to dose NXC-201 patients in U.S.
1y ago
IMMX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
